StockData

Agios Pharmaceuticals vs Precigen

AGIO and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGIO and PGEN compare

Agios Pharmaceuticals is the larger company, worth 1.2 times as much as Precigen ($1.8B against $1.5B).

Agios Pharmaceuticals scores higher on the StockData Score (12 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGIOPGEN
Size and price
Market cap$1.8B$1.5B
Share price$29.89$4.29
Change, 1 year−31.5%−11.5%
Change, 5 years−18.0%11.1%
Beta (5Y)1.541.20
Employees53920
StockData Score
Total score12 (better)2
Valuation score1 (better)0
Growth score3 (better)0
Performance score2 (better)0
Health score6 (better)2
Dividend score00
Valuation
P/S18.1×–
P/B1.7× (better)35.2×
FCF yield−20.5%−7.5% (better)
Fair value$27.70–
Margin of safety−7.9%–
Growth
Revenue growth (TTM)141%–
Revenue growth, 5Y average–−21.3%
Net income growth (TTM)−163%–
EPS growth (TTM)−163%–
Profitability
Gross margin92.0%–
Operating margin−467%–
Net margin−418%–
FCF margin−371%–
Return on equity−34.3% (better)−4640%
Return on invested capital−759%–
Financial health
Debt / equity0.002.15 (better)
Current ratio10.22 (better)4.58
Altman Z-score11.45 (better)−11.14
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions111%39.2%
Held by insiders1.1%44.9%
Insider net buying, 12 months−$4.9M (better)−$32.5M
Superinvestors holding–1
Short interest, % of float11.1%22.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.